Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

NCT03121001 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: ATG
DRUG: fludarabine
DRUG: cyclophosphamide
RADIATION: Total body irradiation
PROCEDURE: Stem cell infusion
DRUG: Sirolimus
DRUG: mycophenolate mofetil

Sponsor

University of Illinois at Chicago